Provided by Tiger Fintech (Singapore) Pte. Ltd.

AlloVir, Inc.

9.65
+0.53005.81%
Post-market: 9.650.00000.00%16:10 EDT
Volume:3.48K
Turnover:33.39K
Market Cap:48.02M
PE:-0.48
High:9.79
Open:9.63
Low:9.46
Close:9.12
Loading ...

AlloVir Shareholders Approve Merger With Kalaris Therapeutics

MT Newswires Live
·
13 Mar

AlloVir trading halted, news pending

TIPRANKS
·
16 Jan

BRIEF-Allovir's Reverse Stock Split Proposal Passes With 96.2 Mln Votes For

Reuters
·
10 Jan

Allovir Inc - Reverse Stock Split Proposal Passes With 96.2 Mln Votes for, 12.1 Mln Against

THOMSON REUTERS
·
10 Jan

AlloVir CEO Departs, CFO Steps In

Dow Jones
·
21 Dec 2024

BRIEF-Allovir Inc - Diana Brainard Steps Down As CEO Of Allovir

Reuters
·
21 Dec 2024

AlloVir Appoints Vikas Sinha as New CEO

TIPRANKS
·
21 Dec 2024

Allovir Inc - Diana Brainard Steps Down as CEO of Allovir

THOMSON REUTERS
·
21 Dec 2024

Allovir Inc: Appointed Vikas Sinha as Company's Chief Executive Officer and "Principal Executive Officer

THOMSON REUTERS
·
21 Dec 2024

Sector Update: Health Care Stocks Edge Higher Premarket Friday

MT Newswires Live
·
08 Nov 2024

AlloVir and Kalaris Merge to Advance Retinal Therapies

TIPRANKS
·
08 Nov 2024

Allovir Inc - Exchange Ratio Assumes Valuation for Allovir of $116.0 Mln and Valuation for Kalaris of $347.0 Mln

THOMSON REUTERS
·
08 Nov 2024

Allovir - Upon Termination of Deal Under Specified Circumstances, Co May Be Required to Pay Kalaris Termination Fee of $3.5 Mln

THOMSON REUTERS
·
08 Nov 2024

AlloVir Shares Slide Premarket on Reverse Merger With Kalaris Therapeutics

Dow Jones
·
08 Nov 2024

AlloVir Signs Merger with Kalaris Therapeutics

MT Newswires Live
·
08 Nov 2024

BRIEF-Allovir And Kalaris Therapeutics Announce Merger To Form Company Focused On Retinal Diseases

Reuters
·
08 Nov 2024